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Abstract
Purpose To evaluate the clinical pharmacology of exoge-
nous alkaline phosphatase (AP).
Methods Randomized, double-blind, placebo-controlled se-
quential protocols of (1) ascending doses and infusion
duration (volunteers) and (2) fixed dose and duration
(patients) were conducted at clinical pharmacology and
intensive care units. A total of 103 subjects (67 male
volunteers and 36 patients with severe sepsis) were
administered exogenous, 10-min IV infusions (three as-
cending doses) or 24–72 h continuous (132.5–200 U kg−1
24 h−1) IV infusion with/without preceding loading dose
and experimental endotoxemia for evaluations of pharma-
cokinetics, pharmacodynamics, safety parameters, antige-
nicity, inflammatory markers, and outcomes.
Results Linearity and dose-proportionality were shown
during 10-min infusions. The relatively short elimination
half-life necessitated a loading dose to achieve stable
enzyme levels. Pharmacokinetic parameters in volunteers
and patients were similar. Innate immunity response was
not significantly influenced by AP, while renal function
significantly improved in sepsis patients.
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Conclusions The pharmacokinetics of exogenous AP is
linear, dose-proportional, exhibit a short half-life, and are
not influenced by renal impairment or dialysis.
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Introduction
Alkaline phosphatases (APs) are dimeric enzymes that are
highly prevalent in nature [1], from bacteria [2] to marine
life [3] to mammals [4]. In man, AP is present in many cells
and organs (e.g., intestines, kidney, placenta, liver, bone,
neutrophils) [5]. Although the dephosphorylating properties
of AP are well characterized [6, 7], its role is not fully
elucidated. A growing body of evidence suggests that AP
plays an important part in host defense in dephosphorylat-
ing extracellular ATP [8, 9], a known pro-inflammatory
molecule, into adenosine, a key molecule in tissue
protection mechanisms [10], while extracellular ATP is
also involved in the activity of phosphatases and phospho-
diesterases [11]. This ecto-enzyme also plays an important
role against inflammatory reactions due to lipopolysaccha-
ride (LPS endotoxin) release during bacterial infection [12,
13].
Prior to large trials testing the role of exogenously
administered AP enzyme in tissue protection during
inflammation such as in cases of sepsis and inflammatory
bowel disease, it is paramount to characterize the clinical
pharmacology of exogenously administered enzyme.
We have conducted three sequential protocols with AP
in humans to evaluate the pharmacokinetics and pharma-
codynamics parameters of intravenously (IV) administered
enzyme. The three sequential studies were randomized and
placebo-controlled, and evaluated the main clinical phar-
macology and safety parameters of exogenous AP in the
presence and absence of experimental human endotoxemia
in volunteers and in patients with severe sepsis.
Methods
The three protocols were conducted sequentially and
included a total of 103 subjects. The dosing escalation
schedules displayed in Table 1 (placebo: n=28; AP: n=75)
proceeded as follows: study A: short, 10-min IV adminis-
tration of ascending AP doses (groups 1–4) and 24-h IV
administration (group 5) in healthy volunteers; study B: 24-
to 72-h IV administration with and without initial 10-min
AP loading dose (groups 6–8) in healthy volunteers; and
study C: 24–h IV administration preceded by 10-min AP
loading dose in sepsis patients. Studies A and B also
included three groups (Table 1: groups 4, 6, and 7)
subjected to experimental endotoxemia for pharmacody-
namics evaluation.
Methods, blinding and subject selection
The first two studies (A and B) were conducted in
volunteers, both were randomized and placebo-controlled,
with 67 subjects enrolled in total (placebo: n=17; AP: n=
50). The studies were conducted at the Clinical Pharmacol-
ogy Unit Antwerp (Belgium), with prior approval by the
appropriate institutional review board (IRB; Commissie
Voor Medische Ethiek – OCMWAntwerpen). Entry criteria
were identical for studies A and B, namely males aged 18–
50 years and considered healthy during medical screening
by a qualified physician, based on medical history, physical
examination, body mass index (BMI) 18–28 kg/m2, vital
signs, blood and urine evaluations, and 12-lead electrocar-
diogram (ECG). All volunteers provided written informed
consent, and the studies were conducted in compliance with
current Guidelines on Good Clinical Practice [14], between
January and June 2003 (study A) and November 2003 and
September 2004 (study B). The aims of both studies were
to evaluate the safety, pharmacokinetics, and pharmacody-
namics of IV administration of exogenous AP. Safety
parameters included tracking adverse events, vital signs,
and changes in ECG, hematology, clinical chemistry,
urinalysis, and immunogenicity. Pharmacokinetics (PK)
parameters were maximum concentration (Cmax expressed
as serum enzyme activity corrected for baseline level), area
under the plasma activity curve (AUC), clearance (CL/
1.73 m2), and elimination half-life (t1/2 measured as time to
achieve 50% or lower activity of the point of enzyme
activity equilibrium, the latter being the level at the end of
the short 10-min infusion, or the level at the end of the 24-
to 72-h infusions).
In two groups receiving short infusions (groups 4 and 7)
and in one group receiving 72-h infusion (group 6), the
volunteers were challenged with LPS endotoxin of 2-min
duration given intravenously 2 min after starting the short
AP infusion or given 2 h after starting the 72-h AP infusion,
to evaluate safety and pharmacodynamics (Table 1). Sam-
ples for PK were taken for groups 1–3 (short 10-min
administration in volunteers) at baseline, 5, 10, 20, 30, 45,
60, and 90 min and 2, 4, and 8 h. Sampling times for the
24-h infusion in volunteers (group 5) were at baseline, 10,
20, 30, 45, and 60 min and 4 and 24 h and then, after the
end of infusion, at 10, 15, 20, 30, 45, and 60 min and 2, 4,
and 8 h. Sampling times for the 72-h infusion in volunteers
(group 8) were at baseline, 10, 30, and 60 min and 1.5, 2, 3,
4, 6, 8, 12, 24, 36, 48, and 72 h and then, after the end of
infusion, at 10, 20, 30, 45, and 60 min and 2, 3, 4, 5, 6, and
7 h. Owing to endogenous enzyme levels playing a
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proportionally larger role in low-dose, short infusions, the
elimination half-life was planned to be re-evaluated during
long infusions with the addition of multiple samplings at
the end of AP infusions in groups 5 and 8.
The third protocol (study C) was conducted in patients
with severe sepsis. The study was randomized and placebo-
controlled and enrolled 36 patients (ratio 1:2; placebo: n=
11; AP: n=25) (Table 1) between September 2004 and
March 2006 at eight intensive care units (ICU) in The
Netherlands and Belgium, with prior approval by the
institutional review board of each hospital and written
informed consent of the patient or next-of-kin. Study
conduct was in compliance with current Guidelines on
Good Clinical Practice [14]. Study C was conducted after
European central trial registration was in place and was
centrally registered (EUDRACT: 2005–005257–21). Entry
criteria were males/females aged 18–80 years with proven
or suspected Gram-negative bacterial infection, at least two
of four Systemic Inflammatory Response Syndrome (SIRS)
criteria for under 24 h and acute-onset end-organ failure
[15] in the preceding 12 h, including hypotension requiring
vasopressor therapy. Exclusion criteria were life-expectancy
less than 24 h, chronic renal failure, acute pancreatitis with
no established source of infection, HIV infection, pregnan-
cy or lactation, confirmed Gram-positive or fungal sepsis,
or use of aminoglycoside antibiotics, immunosuppressants,
or high-dose corticosteroids (≥1 mg kg−1 day−1 prednisone
equivalent).
The aims of study C were to evaluate the safety,
pharmacokinetics, and pharmacodynamics of 24-h IV ad-
ministration (fixed dose: 10-min IV loading followed by
24-h IV infusion) of exogenous AP in sepsis patients with
end-organ dysfunction. Safety parameters included tracking
adverse events, vital signs, and changes in ECG, hematol-
ogy, clinical chemistry, urinalysis, renal parameters, and
immunogenicity. Pharmacokinetics parameters were Cmax
(corrected for baseline level), AUC, clearance (CL/
1.73 m2), and elimination half-life (t1/2 measured as time
to achieve 50% or lower activity at the point of enzyme
activity equilibrium, the latter being the mean activity level
between 18 and 24 h from infusion start). The sampling
times for PK in patients (group 9) were at baseline, 10, 30,
and 60 min and 1.5, 6, 18, and 24 h and then, after the end
of infusion, at 4, 8, and 24 h.
Blinding in all studies was assured by central allocation
of randomization codes in sealed envelopes, audited on
completion of each study, and by supply of study
medication in indistinguishable form (placebo consisted of
same volume, identical appearance, and excipients, except
the enzyme).
For pharmacodynamics evaluations, cytokine measure-
ments [IL-1β, IL-6, IL-8, IL-10, TNFα, and granulocyte-
macrophage colony-stimulating factor (GM-CSF)] were
analyzed centrally by Xendo Biodevelopment Laboratories
(Groningen, The Netherlands) using validated assays for
each cytokine. Antibodies to exogenous AP were mea-
sured centrally by TNO Quality of Life Laboratories
(Zeist, The Netherlands) as total immunoglobulins (Ig),
total IgE, and specific IgG-anti-AP by validated enzyme-
linked immunosorbent assay (ELISA), at baseline, 14, and
21 days post-dosing in volunteers, and at baseline, 14, and
21 days post-dosing in sepsis patients. Skin-prick tests for
sensitization were conducted in studies A and B (volunteers),
with the reaction measured as wheal diameter (+ to ++++)
Table 1 Sequential dosing schedule in studies A, B, and C
All Placebo AP Loading dose (IV) IV infusion
n=103 n=28 n=75 Dose
(U/kg)
Duration
(min)
Dose
(U kg−1 24 h−1)
Duration
(h)
Study A 42 10 32 − − − −
Group 1 8 2 6 7.5 10 − −
Group 2 8 2 6 22.5 10 − −
Group 3 8 2 6 67.5 10 − −
Group 4 10 2 8 67.5 10a − −
Group 5 8 2 6 − − 200 24
Study B 25 7 18 − − − −
Group 6 8 2 6 − − 22.5 72b
Group 7 10 4 6 22.5 10a − −
Group 8 7 1 6 67.5 10 177.5 72
Study C 36 11 25 − − − −
Group 9 20M/16F 5M/6F 15M/10F 67.5 10 132.5 24
Studies A and B were in male healthy volunteers; study C was in sepsis patients of both genders (M males, F females)
a Administration of IV LPS (E. coli EC6, 4 ng/kg) for 2 min after 2 min AP infusion start
b Administration of IV LPS (E. coli EC6, 4 ng/kg) for 2 min after 2 h AP infusion start
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tested for AP, for AP buffer solution, and for two controls
(one negative: NaCl; one positive: histamine). AP enzyme
activity evaluation was by specific kinetic assay described by
Beumer [16].
Study medication (active and placebo) was supplied by
AM-Pharma BV, The Netherlands, as calf-intestinal alka-
line phosphatase in glycerol solution (CAS Registry: EC
3.1.3.1) in 1-mL vials containing AP 5,000 U/mL,
complying with the European Union’s guidelines on
minimization of bovine spongiform encephalopathy (BSE)
risk in medicine manufacture [17], approved by the national
medicines regulatory authority.
Statistics, assignment, and analysis
In each study, randomized treatment allocation was sequen-
tial. Randomization lists were issued as single blocks of
eight (two placebo; six active) for groups 1, 2, 3, 5, 6, and
8 and in single blocks of 10 (two placebo; eight active) for
groups 4 and 7, in studies A and B. For study C,
randomization was in blocks of three with complete blocks
assigned to each ICU. The intention-to-treat (ITT) popula-
tion for safety evaluations was defined in all studies as all
randomized subjects who received any medication. For the
pharmacokinetics analyses, subjects without a baseline
value for AP activity were excluded from all kinetic
calculations. Full datasets were obtained for PK evaluations
from the volunteers in studies A and B, except for one
volunteer in group 8 (study B). In study C, 11 complete
patient datasets were available for PK evaluations, while
safety data were complete for all 36 patients.
Owing to the expected presence of renal failure in
approximately 50% of sepsis patients and dialysis being a
common intervention with an unknown effect on drug
metabolism, pharmacokinetics was evaluated according to
presence/absence of renal failure and/or dialysis, separately.
In patients with renal failure, urinary markers of renal
injury [nitrous oxide (NO) metabolites and glutathione-S-
transferase-A1-1 (GSTA1-1)] were also evaluated. The
sample size for the sepsis study had to be increased
substantially relative to normal volunteers to obtain a
minimum of six complete datasets for pharmacokinetics
evaluations in sepsis with renal failure, estimated as a
minimum of 30% of severe sepsis, to allow meaningful
comparisons with volunteers, and hence a minimum of 36
patients in total were needed for a 2:1 randomization ratio.
All data for the three studies were centrally analyzed by
CRM Biometrics, Rheinbach, Germany, using SAS (ver-
sion 8.2, SAS Institute, Cary, NC, USA; with PROC
Means, Tabulate, Univariate, and Freq, validated against
reference data where appropriate), or WinNonLin Profes-
sional (Pharsight) version 4.0. Means, standard deviations,
medians, ranges, and upper and lower quartiles were
calculated. Pharmacokinetics parameters were listed by
subject, summarized, and evaluated using descriptive
statistics.
Results
Subjects’ characteristics and progress through studies
Dosing schedules are displayed in Table 1 and demograph-
ics data for all three studies at entry are displayed in
Table 2. Owing to limited space, a large volume of data and
the volunteer groups being narrowly defined, the demo-
graphic data are presented as combined AP and placebo
groups for studies A and B. One volunteer randomized to
group 8 (study B; Table 1) tested positive for benzodiaze-
pines during screening before receiving study medication
and was not replaced. All other volunteers in groups
1-8 received study medication as planned and yielded
complete datasets for safety and other analyses. Groups 4,
6, and 7 were planned for safety and pharmacodynamics
evaluations of exogenous AP enzyme during systemic
inflammation induced by experimental endotoxemia, as
these data were required for subsequent studies in sepsis
patients who have large amounts of circulating bacterial
endotoxins.
Pharmacokinetics in healthy volunteers
Demographic data on volunteers are presented in Table 2,
combined for studies A and B as the entry criteria were
identical. Dose proportionality and linearity in pharmaco-
kinetics of exogenous intravenous AP were examined
Table 2 Entry demographic data in studies A and B (healthy
volunteers) and C (sepsis patients)
Healthy
volunteers
(n=67)
Patients (n=36)
Placebo
(n=11)
AP
(n=25)
Mean SD Mean SD Mean SD
Age (years) 36.8 8.1 55.7 18.3 58.7 16.6
Height (cm) 180.6 7.5 172.2 9.4 172.8 9.3
Weight (kg) 77.4 9.5 78.6 14.4 76.5 17.8
BMI (kg/m2) 23.8 2.2 26.6 4.9 25.8 6.2
Systolic BP
(mmHg)
119.6 11.2 110.3 17.4 104.6 18.4
Diastolic BP
(mmHg)
73.6 7.7 61.6 7.1 54.7 9.6
Heart rate (bpm) 61.0 8.9 109.4 25.6 107.2 26.6
BMI Body mass index, BP blood pressure
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during 10-min infusions of trebling ascending doses in
groups 1–3 (7.5, 22.5, and 67.5 U/kg total dose, respec-
tively) administered sequentially to eight (six active; two
placebo) volunteers in each group. Using serum enzyme
activity levels for calculations in a one-compartmental
model, the results suggest that Cmax (Fig. 1 and Table 3)
showed proportionality within the dose range, while the
AUC data also suggest linearity for the three doses.
Elimination half-life (t1/2) and drug clearance were calcu-
lated but, as previously mentioned (see “Methods”), the
long-infusion data from volunteers were better predictors of
patient data.
The next group in the dose escalation (group 5) received
a continuous, 24-h infusion of 200 U/kg (total dose). Main
PK parameters for group 5 are presented in Table 3 and
Fig. 2a, where AUC values in particular led to the
conclusion that a loading dose would be necessary to attain
relatively stable plasma activity of approximately double
the baseline (endogenous) values (mean baseline AP for
volunteers was 74 U/L). Estimated mean elimination half-
life for group 5 was 11.9 h with a fast elimination phase
after discontinuation of infusion, while mean clearance was
7.2 L/h. Although the data may suggest a long, second
elimination phase, this was influenced by food intake,
which increases endogenous enzyme activity, and it was
impossible to demand near-fasting conditions from volun-
teers beyond 24 h.
The next group of dose escalation (group 8) for PK
evaluations received an initial 10-min loading dose of
67.5 U/kg followed by continuous infusion of 177.5 U kg−1
24 h−1 for 72 h. Mean Cmax values reflected the loading
dose (group 8, Table 3 and Fig. 2b). The results for group
8 highlight the difficulties in evaluating pharmacokinetics
of AP enzyme: the median Cmax for group 8 was 55% lower
than for group 3 despite both groups having the same
demographic characteristics and having received the same
dose for the first 10 min. Mean and median AUC0–24 were
very similar and served as a basis for subsequent
comparative kinetics in patients. Elimination half-life was
approximately 8 h and mean enzyme clearance was 4.7 L/h.
The results for group 8 confirmed that a loading dose would
be needed to attain higher stable levels of enzyme activity
in the following patient study.
Pharmacokinetics in sepsis patients
Sepsis patients (group 9) received a 10-min loading dose of
67.5 U/kg followed by continuous infusion of 132.5 U/kg
for 24 h. All PK parameters were evaluated for the three
sepsis subgroups, namely, patients without acute renal
failure and not on renal replacement therapy (RRT;
dialysis) (group 9.1; n=5), patients with renal failure
without RRT (group 9.2; n=4), and patients with renal
failure on RRT (group 9.3; n=2) (Table 3). There were no
significant differences in any of the main PK parameters
across patient groups.
Although there were only two patients receiving RRT
(group 9.3), no major differences were detected relative to
those without acute renal failure or with acute renal failure
not on RRT. Mean Cmax reflected the loading dose in the
three sepsis sub-groups (range of means: 246–317 U/L),
very similar to values obtained in group 8 (volunteers), who
had received an identical loading dose. AUC0–24 in patients
(range of medians: 1,063–1,121 U h−1 L−1) was comparable
to volunteers in group 8 (median: 1,105 U h−1 L−1).
Enzyme clearance was 7.0–7.5 L/h across patient sub-
groups. Overall, the patient data were within the overall
variability range of volunteers.
Samples at three time-points post-treatment (4, 8, 24 h)
were collected for estimation of whether elimination t1/2
had been achieved at these points, defined as activity level
≤50% of mean activity at 18–24 h infusion. Elimination t1/2
was ≤4 h for one patient, 4–8 h for six patients, and
slightly longer than 8 h for four patients, similar to
volunteers in groups 5 and 8 who had received ≥24 h
infusion and for whom we had robust elimination data.
Regardless of the parameter, the patient data did not
suggest that the pharmacokinetics of exogenous AP is
affected in any appreciable manner by the profound
metabolic abnormalities that accompany severe sepsis,
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Fig. 1 Dose-proportionality and linearity (10-min infusion). a Serum
activity data points are medians and interquartile ranges. b Area under
the curve (AUC) data points are arithmetic means
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whether or not patients sustained acute renal failure or
received RRT.
Pharmacodynamics evaluations
There were no changes in any of the pharmacodynamics
evaluations in volunteers receiving AP infusions without
LPS challenge (groups 1, 2, 3, 5, and 8).
In the groups receiving LPS challenge (groups 4, 6,
and 7), a febrile response was observed for up to 8 h
after LPS injection, but there were no differences in body
temperature and vital signs between placebo and AP-
treated volunteers before, during, or after challenge.
Body temperature increased 4–8 h (maximum at 6 h;
mean±SD=2.1±0.7°C) post-endotoxin, returning to nor-
mal within 24 h. Other vital signs followed the pattern of
febrile response although the changes were shorter-lived
(up to 4 h post-challenge), returning to baseline thereaf-
ter. In the same groups, there was an increase in
peripheral blood neutrophil count with relative decreases
in eosinophils, basophils, lymphocytes, and monocytes
1–10 h after LPS injection, all of which were expected
post-endotoxin challenge and indistinguishable across
treatment groups.
Evaluation of cytokine response in groups 4, 6, and 7
(group 7 displayed in Fig. 3) showed increases in the
response of circulating cytokines to endotoxemia as
expected (minimally for IL-1 β) but, although mean values
of all cytokines’ response were lower on AP, there were no
significant differences relative to placebo, which suggests
that AP may not influence systemic cytokine levels
substantially.
In sepsis patients, cytokines exhibited large inter- and
intrapatient variability, with no relevant differences being
observed among treatment groups. Likewise, no other
systemic inflammatory parameters yielded robust or con-
sistent evidence of marked differences among groups that
could be considered clinically meaningful; hence these data
Table 3 Pharmacokinetics parameters of exogenously administered AP
10-min infusion
(volunteers)
≥24-h infusion
(volunteers)
24-h infusion
(sepsis patients)
Group 1
(n=6)
Group 2
(n=6)
Group 3
(n=6)
Group 5
(n=6)
Group 8
(n=5)
Group 9.1: no ARF,
no dialysis (n=5)
Group 9.2: ARF,
no dialysis (n=4)
Group 9.3: ARF,
on dialysis (n=2)
Cmax (U/L) Mean 82.8 167.3 501.2 61.8 272.4 275.1 245.8 317.1
SD 17.4 45.6 86.6 13.2 33.4 110.4 51.2 101.9
Median 84.0 179.6 522.4 56.0 290.4 273.5 240.2 317.1
Min 62.4 95.2 346.4 50.7 219.3 132.1 189.3 245.0
Max 111.2 216.0 578.4 85.0 299.4 440.9 313.4 389.1
AUC0–24 (U·h/L) Mean − − − 1,282.3 1,084.3 1,122.3 1,267.4 1,063.4
SD − − − 345.3 167.4 347.5 272.0 98.6
Median − − − 1,147.7 1,105.1 1,121.5 1,107.0 1,063.4
Min − − − 1,022.7 920.2 627.9 1,026.6 993.7
Max − − − 1,914.0 1,330.4 1,519.9 1,659.5 1,133.2
AUC0–oo(U·h/L) Mean 364.4 405.7 642.5 2,005.1 3,472.8 1,911.9 2,134.2 1,832.3
SD 175.7 176.5 192.4 375.7 574.9 453.6 332.1 286.1
Median 330.9 367.9 588.0 1,972.7 3,484.1 2,011.0 2,014.3 1,832.3
Min 163.1 265.2 469.5 1,396.0 2,913.6 1,425.8 1,901.9 1,630.0
Max 695.0 754.6 984.5 2,407.7 4,360.7 2,538.3 2,606.4 2,034.6
CL/1.73 m2 (L/h) Mean 1.6 4.1 7.8 7.2 4.7 7.2 7.0 7.5
SD 0.8 1.1 1.9 1.5 0.8 2.0 2.2 1.2
Median 1.6 4.5 8.1 7.1 5.0 6.5 6.4 7.5
Min 0.7 2.1 5.0 5.7 3.8 5.1 5.2 6.7
Max 3.0 5.5 9.8 10.0 5.7 9.5 10.2 8.4
t1/2 (h) Mean 12.2 5.0 3.8 11.9 8.3 − − −
SD 8.6 1.0 0.3 5.9 0.7 − − −
Median 10.1 5.1 3.8 12.4 8.5 − − −
Min 4.1 3.7 3.5 5.6 7.5 − − −
Max 28.5 6.7 4.4 17.4 9.1 − − −
ARF Acute renal failure
Doses: group 1: 7.5 U/kg, group 2: 22.5 U/kg, group 3: 67.5 U/kg, group 5: 200 U kg−1 24 h−1 (24-h infusion), group 8: 67.5 U/kg (10 min) +
177.5 U kg−1 24 h−1 (72-h infusion), group 9: 67.5 U/kg (10 min) + 132.5 U kg−1 24 h−1 (24-h infusion)
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are not tabulated. Plasma lactate was significantly lower in
AP-treated patients on days 2 and 4 after treatment (P<
0.04), but the relevance of this finding in the absence of
other changes in systemic inflammatory markers is uncer-
tain. Differences in pharmacodynamics between treatment
groups were confined to clinical outcomes related to acute
renal failure as previously reported [18], with all-cause
mortality rates of 60 and 27% on placebo and AP,
respectively, while dialysis intervention was required in
80 and 36% of patients, respectively. The parameters
related to acute kidney injury were in line with clinical
outcomes and have been reported elsewhere [18], with
serum creatinine and cumulative urinary excretion of GSTA1-
1 being considerably lower in AP-treated patients and
correlating with NO metabolite excretion (rs=0.5; P<0.01).
Safety results
The main adverse events from the safety evaluations are
presented in Table 4. Exogenous administration of AP did
not raise safety concerns in volunteers or sepsis patients. In
volunteers, the most common event was headache, reported
both on placebo (65%) and on AP (40%). In sepsis patients,
the most frequently reported event was “general condition
aggravated,” reported by 18% on placebo and 12% on AP.
No antibodies against AP were detected (specific IgG-
anti-AP, total immunoglobulins, or IgE) in volunteers or
patients up to 21 days post-administration, while skin-prick
tests were negative in volunteers and, consequently, not
evaluated in patients. Clinical laboratory (hematology,
biochemistry, urinalysis) and 12-lead ECGs (including QT-
interval) did not suggest treatment-related abnormalities.
Challenge with LPS endotoxin in volunteers was
associated with myalgia and rigors, similarly on placebo
and AP (Table 4). The tolerability of exogenous AP in
patients with circulating endotoxins was subsequently
confirmed in group 9 (sepsis patients).
Discussion
Knowledge of clinical pharmacology of drugs in patients
with sepsis is scarce despite profound sepsis-induced
pathophysiological changes in these patients often affecting
drug absorption, distribution, metabolism, and excretion
[19]. Mammalian APs are membrane-bound enzymes; and
in humans, four AP isoenzymes exist of which three are
tissue-specific (placental, PLAP; germ cell, GCAP; and
intestinal, IAP) and one is tissue nonspecific (TNAP) and is
expressed in virtually all tissues (e.g., bone, liver, and
kidney). This hydrolase removes phosphate groups from
pro-inflammatory molecules [8–12], dephosphorylation
being a key mechanism in host defense against inflamma-
tion, whether due to exogenous toxins such as bacterial
LPS or to endogenous extracellular ATP [20, 21], the latter
having a potent pro-inflammatory activity [22]. AP admin-
istration may enhance endogenous dephosphorylating ca-
pacity when the need is greatest, such as during acute
inflammatory response, to reduce local tissue damage and
to retain organ function. Animal models of sepsis have
shown exogenous AP to attenuate the inflammatory
response and to improve tissue damage and outcomes [16,
23]
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Fig. 2 Mean serum AP activity (long infusions >24 h) for groups 5
(a), 8 (b), and 9 (c). Serum activity data points are medians and
interquartile ranges. ARF Acute renal failure
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Evaluation of the pharmacokinetics of exogenous AP in
humans is complex because the enzyme is also produced
endogenously and the activities of endogenous and exog-
enous enzymes are indistinguishable. We corrected enzyme
values for pre-dosing activity, although this does not
completely exclude interference from endogenous varia-
tions due to circadian and food influences. We controlled
endogenous interference in volunteers through fasting,
bearing in mind that it is impossible to totally abolish
interference from endogenous enzyme physiologically or in
pathology. Therefore, while Cmax and AUC of short
infusions with low doses of AP showed linearity of enzyme
activity in relation to dosing, short infusions were poor
predictors of elimination and clearance during long infu-
sions. Nevertheless, the linearity and dose-proportionality
of AUCs after administration of ascending doses of
exogenous enzyme demonstrate that the AUC is related to
exogenous enzyme administration.
We also found during the dose escalation that to achieve
(over a period of at least 24 h) approximately double the
baseline level of endogenous enzyme activity, a loading
dose is required, without which the ascending activity curve
is too shallow to yield end-organ-protective enzyme levels
for the metabolic assault of LPS or extracellular ATP
expected in sepsis. This was corroborated by our patient
data suggesting that exogenous AP may affect local end-
organ parameters (kidney) and related clinical outcomes but
not systemic markers of inflammatory response (circulating
cytokines). The estimation of ideal serum activity is all the
more complex because the accepted normal range of AP in
serum is too wide to reflect the values we found in our
volunteers and patients. The literature refers to 20-200 U/L
AP serum activity [24, 25], yet the top-end of normal is
justified but not typically observed except after food,
alcohol, and other “normal” activities, whereas abnormal
levels tend to be multiples of the upper limit of normal.
There is no evidence from literature that high levels of AP
are harmful per se, enzyme level denoting tissue effort to
repair damage rather than the enzyme itself being toxic or
damaging [26, 27].
Our data suggest that relatively stable serum AP
activity can be achieved at a level that is approximately
double that of endogenous enzyme for a period of 24–72 h
by administering a loading dose of 67 U/kg followed by a
continuous infusion of 132–177 U kg−1 24 h−1, due to fast
elimination time, which for a 140-kD protein reflects
metabolism rather than excretion. Our data also show that,
without a loading dose, it is not possible to increase serum
enzyme activity substantially within 24 h, which is an
important factor in acute intervention, e.g., in sepsis
patients. Importantly, the safety data from 103 subjects
in our studies do not suggest that exogenous AP causes
any detectable adverse effects in humans in the dose range
we tested.
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The results also show that the pharmacokinetics of
exogenously administered AP is similar in volunteers and
patients, not altered substantially, if at all, by the presence
of systemic inflammation in severe sepsis with or without
acute renal failure and, although data on dialysis patients
were limited, there was no indication of any differences in
this subset.
The current characterization of the clinical pharmacolo-
gy parameters of exogenous AP is complex due to AP
being part of human economy, but it was paramount to
enable further research of this enzyme in the treatment of
acute renal failure in sepsis and other clinical settings where
extracellular ATP and/or LPS play a role, such as in
postoperative vascular-origin acute renal failure and in-
flammatory bowel disease, where there is an urgent need
for effective treatments. However, there are limitations on
the use of animal-origin enzyme, due to difficulties in
obtaining bovine enzyme from BSE-free sources and the
risk of immune reactions after repeated exposure. Although
we did not detect antibody formation in volunteers or
patients, it is highly likely that animal-sourced AP will
elicit immune reactions if repeated or given for longer
periods [28]. We are advised by the manufacturers that a
recombinant human form of AP will become available
shortly, which will allow repeated administration in future.
Until such time intravenous AP should be tried as a once-
only treatment.
Conclusions
Exogenous intravenous administration of AP enzyme
exhibits linear kinetics and dose proportionality during
short infusions in the dose range 22.5–67.5 U/kg. Contin-
uous IV infusions of exogenous AP in the range 132.5–
177.5 U kg−1 24 h−1 preceded by a loading dose of 67.5 U/kg
can achieve relatively stable serum enzyme activity over
periods of 24–72 h that are approximately twice the level of
endogenous enzyme. Clearance of exogenous AP given as
continuous infusion is in the range 5.2–7.5 L/h, and
elimination half-life is 8–12 h in humans. While the data
we accrued provide clinical pharmacology parameters for
larger therapeutic trials, preliminary data from patients
suggest that exogenous AP administration in severe sepsis
patients may play a renal protective role, possibly via
dephosphorylation of extracellular ATP and LPS, that is
worth further clinical investigation.
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Table 4 Safety and tolerability data (n=103)
Placebo, n (%) AP, n (%)
Groups 1–8 (healthy volunteers) (n=17) (n=50)
All adverse events 46 93
Subjects with reported events 11 (65%) 27 (54%)
Serious adverse events 0 0
Events reported in >1 volunteer
Headache 11 20
Rigors 7 11
Dizziness 5 7
Nausea/vomiting 4 7
Back pain 3 4
Feeling cold − 4
Feeling hot 1 4
Fatigue 1 3
Nasal congestion − 3
Flu-like illness − 2
Injection-site reaction − 2
Myalgia 2 2
Group 9 (sepsis patients) (n=11) (n=25)
Adverse eventsa 16 34
Patients with reported events 7 (64) 17 (68)
Serious adverse events (SAE)b 7 (64) 10 (40)
Treatment-related SAEc 3 (27) −
Death (all-cause) 4 (36) 6 (24)
Treatment-related deathc 1 (9) −
Events reported in >1 patient
General condition aggravated 2 3
Herpes simplex 1 2
Atrial fibrillation 3 −
Increased liver enzyme − 2
Pruritus − 2
Troponin increased − 2
Sepsis aggravated 2 −
a Includes multiple events in one patient, considered possibly or
definitely treatment-related
b Life-threatening, or causing death or prolongation of hospitalization
c Reported blindly (before code-break) by physician as possibly
treatment-related
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